Effect of MK-386, a novel inhibitor of type 1 5α-reductase, alone and in combination with finasteride, on serum dihydrotestosterone concentrations in men

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 8, 1996, Pages 2942-2947

  Schwartz, Jules I ^a   Van Hecken, Anne ^b   De Schepper, Paul J ^b   De Lepeleire, Inge ^a   Lasseter, Kenneth C ^c   Shamblen, E Cooper ^c   Winchell, Gregory A ^a   Constanzer, Marvin L ^a   Chavez, Cynthia M ^a   Wang, Daniel Z ^a   Ebel, David L ^a   Justice, Steven J ^a   Gertz, Barry J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Clinical Pharmacology Associates Miami   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4,7BETA DIMETHYL 4 AZACHOLESTAN 3 ONE; ANDROSTANOLONE; FINASTERIDE; PLACEBO; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE METABOLISM; TISSUE DISTRIBUTION;

ADULT; AZASTEROIDS; CHOLESTENONE 5 ALPHA-REDUCTASE; DIHYDROTESTOSTERONE; DOUBLE-BLIND METHOD; DRUG SYNERGISM; FINASTERIDE; HUMANS; MALE; OSMOLAR CONCENTRATION; OXIDOREDUCTASES;

EID: 10144251748     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.81.8.2942     Document Type: Article

References (45)

1. Ito T, Horten R. 1982 The source of plasma dihydrotestosterone in man. J Clin Invest. 3:1-25.
2. Martini L. 1982 The 5α-reduction of testosterone in the neuroendocrine structures: biochemical and physiologic implications. Endocr Rev. 3:1-25.
3. Wilson JD, Walker JD. 1969 The conversion of testosterone to 5α-androstane-17-ol-3-one (dihydrotestosterone) by skin slices of man. J Clin Invest. 48:371-379.
4. Wilson JD. 1970 The intranuclear metabolism of testosterone in the accessory organs of reproduction. Recent Prog Horm Res. 26:309-336.
5. Imperato-McGinley J, Guerrero L, Gautier T, et al. 1974 Steroid 5α-reductase deficiency in man: an inherited form of male pseudohermaphroditism. Science. 186:1213-1215.
6. Walsh PC, Madden JD, Harrod MJ, et al. 1974 Familial incomplete male pseudohermaphroditism, type 2: decreased dihydrotestosterone formation in pseudovaginal perineoscrotal hypospadias. N Engl J Med. 291:944-949.
7. Gormley GJ, Stoner E, Bruskewitz RC, et al. 1992 The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med. 327:1185-1191.
8. Price VH. 1975 Testosterone metabolism in the skin. Arch Dermatol. 111:1496-1502.
9. Tenover JS. 1991 Prostates, pates, and pimples-the potential medical uses of steroid 5α-reductase inhibitors. Endocrinol Metab Clin North Am. 20:893-909.
10. Rittmaster RS. 1995 Medical treatment of androgen-dependent hirsutism. J Clin Endocrinol Metab. 80:2559-2563.
11. Bingham KD, Shaw DA. 1973 The metabolism of testosterone by human male scalp skin. J Endocrinol, 57:111-121.
12. Schweikert HU, Wilson JD. 1974 Regulation of human hair growth by steroid hormones. I. Testosterone metabolism in isolated hairs. J Clin Endocrinol Metab. 38:811-819.
13. Schmidt JA, Schweikert HU. 1986 Testosterone and epitestosterone metabolism of single hairs in five patients with 5α-reductase-deficiency. Acta Endocrinol (Copenh). 113:588-592.
14. Andersson SR, Bishop RW, Russell DW. 1989 Expression cloning and regulation of steroid 5α-reductase, an enzyme essential for male sexual differentiation. J Biol Chem. 264:16249-16255.
15. Andersson S, Russell DW. 1990 Structure and biochemical properties of cloned and expressed human and rat steroid 5α-reductases. Proc Natl Acad Sci USA. 87:3640-3644.
16. Andersson S, Berman DM, Jenkins EP, et al. 1991 Deletion of steroid 5α-reductase 2 gene in male pseudohermaphroditism. Nature 354:159-161.
17. Jenkins EP, Andersson S, Imperato-McGinley, et al. 1992 Genetic and pharmacological evidence for more than one human steroid 5α-reductase. J Clin Invest. 89:293-300.
18. Harris G, Azzolina B, Baginsky W. 1992 Identification and selective inhibition of an isozyme of steroid 5α-reductase in human scalp. Proc Natl Acad Sci USA. 89:10787-10791.
19. Rasmusson GH. 1987 Biochemistry and pharmacology of 5α-reductase inhibitors. In: Furr BJA, Wakeling AE, eds. Pharmacology and clinical uses of inhibitors of hormone secretion and action. London: Bailliere Tindall; 308-325.
20. Tolman RL, Aster S, Bakshi RK, et al. 1995 4-Azasteroids as 5α-reductase inhibitors: identification of 4,7β-dimethyl-4-AZA-5α-cholestan-3-one (MK-386) as a scalp isozyme selective inhibitor. Eur J Med Chem. 30(Suppl): 311s-316s.
21. McConnell JD, Wilson JD, George FW, et al. 1992 Finasteride, an inhibitor of 5α-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 74:505-508.
22. Imperato-McGinley J, Peterson RE, Gautier T, et al. 1982 Hormonal evaluation of a large kindred with complete androgen insensitivity: evidence for secondary 5α-reductase deficiency. J Clin Endocrinol Metab. 54:931-941.
23. Thiboutot D, Harris G, Iles V, et al. 1995 Activity of the type 1 5α-reductase exhibits regional differences in isolated sebaceous glands and whole skin. J Invest Dermatol. 209-214.
24. Shapiro SS, Wilk MB. 1965 Analysis of variance test for normality (complete samples). Biometrika. 52:591-611.
25. Levene H. 1960 Robust tests for equality of variances-contributions to probability and statistics. Stanford University Press: Palo Alto; 278-292.
26. Furuyama S, Mayes DH, Nugent CA. 1970 Radioimmune assay for plasma testosterone. Steroids. 16:415-428.
27. Yeh KC, Kwan KC. 1978 A comparison of numerical integrating algorithms by trapezoidal, lagrange, and spline approximations. J Pharmacokinet Biopharm. 6:79.
28. Piro CF, Fraioli F, Sciarra F, et al. 1973 Rhythm of plasma testosterone, cortisol and gonadotropins in normal male subjects. J Steroid Biochem. 4:321-329.
29. Tenover JS, Matsumoto AM, Clifton DK, et al. 1988 Age-related alterations in the circadian rhythms of pulsatile futeinizing hormone and testosterone secretion in healthy men. J Gerontol. 43:M163-M169.
30. Nieschlag E. 1974 Circadian rhythm of plasma testosterone. In: Aschoff J, Ceresa F, Halberg F, eds. Chronobiological aspects of endocrinology. Stuttgart: Schattauer Verlag; 117-128.
31. Van Hecken A, Depre M, Schwartz Jl, et al. 1994 Plasma concentrations and effect on testosterone metabolism after single doses of MK-0434, a steroid 5α-reductase inhibitor, in healthy subjects. Eur J Clin Pharmacol. 46:123-126.
32. Schwartz JI, Laskin OL, Meeter CA, et al. 1994 Pharmacodynamics of MK-0963, a new 5α-reductase inhibitor: effects on serum androgen concentrations. Clin Pharmacol Ther. 55:50-54.
33. Pochi PE. 1988 Acne: androgens and microbiology. Drug Dev Res. 13:157-168.
34. Harris HH, Downing DT, Stewart ME, et al. 1983 Sustainable rates of sebum secretion in acne patients and matched normal control subjects. J Am Acad Dermatol. 8:200-203.
35. Pochi PE. 1990 The pathogenesis and treatment of acne. Annu Rev Med. 41:187-198.
36. Pochi PE. 1982 Androgenic effects on human sebaceous glands. Arch Dermatol. 118:803-804.
37. Pochi PE. 1982 Hormones and acne. Semin Dermatol. 1:265-273.
38. Strauss JS, Kligman AM, Pochi PE. 1962 The effect of androgens and estrogens on human sebaceous glands. J Invest Dermatol. 39:139-155.
39. Miller JA, Wojnarowska FT, Dowd PM, et al. 1986 Anti-androgen treatment in women with acne: a controlled trial. Br J Dermatol. 114:705-716.
40. Goodfellow A, Alaghband-Zadeh J, Carter G, et al. 1984 Oral spironolactone improves acne vulgaris and reduces sebum excretion. Br J Dermatol. 111:209-214.
41. Greenwood R, Brummitt L, Burke B, et al. 1985 Acne: double blind clinical and laboratory trial of tetracycline, oestrogen-cyproterone acetate, and combined treatment. Br Med J. 291:1231-1235.
42. Cunliffe WJ. 1982 Acne, hormones, and treatment. Br Med J. 285:912-913.
43. Pye RJ, Meyrick G, Pye MJ, et al. 1977 Effect of oral contraceptives on sebum excretion rate. Br Med J. 17:1581-1582.
44. Takayasu S, Wakimoto H, Itami S, et al. 1980 Activity of testosterone 5α-reductase in various tissues of human skin. J Invest Dermatol. 74:187-191.
45. Imperato-McGinley J, Gautier T, Cai L, et al. 1993 The androgen control of sebum production. Studies of subjects with dihydrotestosterone deficiency and complete androgen insensitivity. J Clin Endocrinol Metab. 76:524-528.